ABBOTT INDIA LIMITED
- Country
- 🇮🇳India
- Ownership
- Private
- Established
- 1888-01-01
- Employees
- 73K
- Market Cap
- $7.5B
- Website
- http://www.abbott.com
Study of Lopinavir, Ritonavir, Tenofovir and Emtricitabine in HIV-Infected Antiretroviral Naïve Subjects
- Conditions
- HIV Infections
- First Posted Date
- 2002-08-19
- Last Posted Date
- 2006-07-27
- Lead Sponsor
- Abbott
- Target Recruit Count
- 200
- Registration Number
- NCT00043966
- Locations
- 🇺🇸
Phoenix Body Positive, Phoenix,, Arizona, United States
🇺🇸Akron Infectious Disease, Inc., Akron, Ohio, United States
🇺🇸Donna E. Sweet, MD, Wichita,, Kansas, United States
A Study of Two Different Doses of ABT-378/Ritonavir in HIV-Infected Patients Who Have Taken Protease Inhibitors and Non-Nucleoside Reverse Transcriptase Inhibitors
- Conditions
- HIV Infections
- First Posted Date
- 2002-06-04
- Last Posted Date
- 2006-08-15
- Lead Sponsor
- Abbott
- Target Recruit Count
- 36
- Registration Number
- NCT00038636
- Locations
- 🇪🇸
Hospital Clinico de Barcelona, Barcelona, Spain
🇪🇸Ciutat Sanitaria de Bellvitge, Barcelona, Spain
🇺🇸Johns Hopkins Hospital, Baltimore, Maryland, United States
Safety and Efficacy of Atrasentan in Men With Hormone Naive Prostate Cancer Exhibiting Early Signs of Biochemical Failure
- Conditions
- Prostatic Neoplasms
- First Posted Date
- 2002-06-04
- Last Posted Date
- 2006-08-15
- Lead Sponsor
- Abbott
- Target Recruit Count
- 200
- Registration Number
- NCT00038662
- Locations
- 🇺🇸
Carolinas Medical Centre, Charlotte,, North Carolina, United States
🇺🇸Urologic Specialists Of Oklahoma, Inc., Tulsa,, Oklahoma, United States
🇺🇸Center for Urologic Care, West Reading, Pennsylvania, United States
Amprenavir/Ritonavir or Saquinavir/Ritonavir in HIV-Infected Subjects Following Failure With Kaletra as Their Second Protease Inhibitor
- Conditions
- HIV Infections
- First Posted Date
- 2002-06-03
- Last Posted Date
- 2006-07-28
- Lead Sponsor
- Abbott
- Target Recruit Count
- 16
- Registration Number
- NCT00038519
- Locations
- 🇨🇦
Toronto General Hospital Division of The University Health Network, Toronto, Ontario, Canada
🇨🇦Phillip Sestak, M.D, Vancouver, British Columbia, Canada
🇵🇱Wojewodzki Szpital Zakazny, Warszawa, Poland
Amprenavir/Ritonavir, Saquinavir/Ritonavir or Efavirenz in HIV-Infected Subjects Following Failure With Kaletra (ABT-378/Ritonavir) as Their First Protease Inhibitor Based HAART
- Conditions
- HIV Infections
- First Posted Date
- 2002-06-03
- Last Posted Date
- 2008-04-01
- Lead Sponsor
- Abbott
- Target Recruit Count
- 24
- Registration Number
- NCT00038532
- Locations
- 🇨🇦
Toronto General Hospital Division of The University Health Network, Toronto, Ontario, Canada
🇺🇸University of Cincinnati Medical Center, Cincinnati, Ohio, United States
🇺🇸Diversified Medical Practices, P.A., Houston, Texas, United States
Effectiveness of ABT-378/Ritonavir Plus Lamivudine Plus Efavirenz Plus Tenofovir DF in HIV-Infected Patients
- Conditions
- HIV Infections
- First Posted Date
- 2002-05-30
- Last Posted Date
- 2006-07-27
- Lead Sponsor
- Abbott
- Target Recruit Count
- 40
- Registration Number
- NCT00038220
- Locations
- 🇺🇸
Aaron Diamond AIDS Research Center - Rockefeller University, New York, New York, United States
Study of Atrasentan in Men With Non-Metastatic, Hormone-Refractory Prostate Cancer
- Conditions
- Prostatic Neoplasms
- First Posted Date
- 2002-05-13
- Last Posted Date
- 2007-08-15
- Lead Sponsor
- Abbott
- Target Recruit Count
- 941
- Registration Number
- NCT00036556
- Locations
- 🇺🇸
Ntouch Research Corporation, Dallas, Texas, United States
🇨🇦Princess Margaret Hospital, Toronto, Ontario, Canada
🇺🇸UCLA School of Medicine, Los Angeles, California, United States
A Study of Atrasentan in Men With Metastatic, Hormone-Refractory Prostate Cancer
- Conditions
- Prostate Cancer
- First Posted Date
- 2002-05-13
- Last Posted Date
- 2006-08-15
- Lead Sponsor
- Abbott
- Target Recruit Count
- 1000
- Registration Number
- NCT00036543
- Locations
- 🇨🇦
Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
🇺🇸Alaska Clinical Research Center, LLC, Anchorage, Alaska, United States
🇺🇸Clinical Physiology Associates, Fort Myers, Florida, United States
Phase I Safety Study of Anti-HIV Immune Serum Globulin (Human)
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2009-02-20
- Lead Sponsor
- Abbott
- Target Recruit Count
- 12
- Registration Number
- NCT00002036
- Locations
- 🇺🇸
Univ of Minnesota, Minneapolis, Minnesota, United States
The Safety and Effectiveness of Clarithromycin in the Prevention of Mycobacterium Avium Complex (MAC) Infection in HIV-Infected Patients
- Conditions
- HIV InfectionsMycobacterium Avium-intracellular Infection
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2015-01-16
- Lead Sponsor
- Abbott
- Registration Number
- NCT00002336
- Locations
- 🇺🇸
Dr Nelson Zide, Hollywood, Florida, United States
🇺🇸Houston Veterans Administration Med Ctr, Houston, Texas, United States
🇺🇸Univ of Arizona / Health Science Ctr, Tucson, Arizona, United States